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Abstract
Colorectal cancer is the third most common malignancy
worldwide, with 1.3million new cases annually. Metastasis to
the liver is a leading cause of mortality in these patients. In
human liver,metastatic cancer cellsmust evade populations of
liver-resident natural killer (NK) cells with potent cytotoxic
capabilities. Here, we investigated how these tumors evade
liver NK-cell surveillance. Tissue biopsies were obtained from
patients undergoing resection of colorectal liver metastasis
(CRLM, n ¼ 18), from the tumor, adjacent tissue, and distal
resectionmargin. The number and phenotype of liver-resident
NK cells, at each site, were analyzed by flow cytometry. Tumor-
conditioned media (TCM) was generated for cytokine and
metabolite quantification and used to treat healthy liver-
resident NK cells, isolated from donor liver perfusate during
transplantation. Liver-resident NK cells were significantly
depleted from CRLM tumors. Healthy liver-resident NK cells
exposed to TCM underwent apoptosis in vitro, associated with
elevated lactate. Tumor-infiltrating liver-resident NK cells
showed signs ofmitochondrial stress, which was recapitulated
in vitro by treating liver-resident NK cells with lactic acid. Lactic
acid induced apoptosis by decreasing the intracellular pH of
NK cells, resulting inmitochondrial dysfunction that could be
prevented by blocking mitochondrial ROS accumulation.
CRLM tumors produced lactate, thus decreasing the pH of
the tumor microenvironment. Liver-resident NK cells
migrating toward the tumor were unable to regulate intracel-
lular pH resulting in mitochondrial stress and apoptosis.
TargetingCRLMmetabolismprovides a promising therapeutic
approach to restoring local NK-cell activity and preventing
tumor growth.
Introduction
Colorectal cancer represents a major health problem world-
wide, with more than 1.3 million new cases per year (1).
Advancing age of populations globally and rising rate of obesity
are driving increasing rates of colorectal cancer (2). Metastasis is
a major cause of morbidity and mortality in colorectal cancer
patients. In the absence of distant metastases (stages I–III),
5-year survival ranges between 70% and 90%; however, in
patients with metastatic disease (stage IV), this is only 14%
(3). The liver is the most common site of distant metastasis,
with up to 50% of patients developing colorectal liver metas-
tasis (CRLM; refs. 4, 5). However, it remains unknown how
metastatic colorectal cells colonize an immunocompetent
organ and avoid local immunosurveillance.
The adult human liver contains an extensive repertoire of
antitumor immune cells. Innate lymphoid cells, including natural
killer (NK) cells, natural killer T (NKT) cells, mucosal associated
invariant T (MAIT) cells, and gd T cells, predominate in the liver.
Conventional CD4þ and CD8þT cells are also present, with an
increased proportion of cytotoxic CD8þ T cells (6–11). NK cells
are group 1 innate lymphoid cells (ILC), important in antiviral
and tumor immunity, and in particular the control of metastasis
(12), with NK-cell therapies currently being trialed for the treat-
ment of CRLM (13). The human liver contains resident NK cells
possessing enhanced antitumor activity characterized by
increased degranulation (14–16). These cells are characterized
as CD56bright NK cells, express the chemokine receptor CXCR6,
and have a unique transcription factor profile (EomeshiTbetlo).
The evidence that immune infiltration of colorectal cancer is a
determinant of disease outcomehas led to the development of the
Immunoscore as a routine diagnostic test (17–19). The density of
T- and NK-cell infiltration of CRLM tumors has been shown to
positively predict survival (20). However, infiltration of T andNK
cells was highly variable, and some tumors were almost devoid of
NK cells. NK cells appear to play a central role in the outcome
of CRLM, demonstrated by their depletion and compromised
function in primary colorectal cancer tumors and blood (21, 22).
It remains unknown whether liver-resident NK cells are dysfunc-
tional in metastases to the liver. We believe this loss of immu-
nosurveillance is in part driven by the unique tumor microenvi-
ronment. The liver microenvironment is dramatically altered in
the presence of CRLM (23–25), and the metabolic changes
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associated with tumor growth can have profound effects on
infiltrating immune cells, especially T andNK cells, which require
metabolic reprogramming upon activation (26–29).
In this study, we have characterized the distribution of liver-
resident NK cells in different regions of tumor-bearing liver,
tumor, tumor adjacent, and distal tissue from the resection
margin. Using in vitro culture techniques, generating conditioned
media from tumor and healthy tissue, we have identified lactate,
a metabolite of glycolysis, which induces the apoptosis of liver-
resident NK cells. This pathway provides the rationale for poten-
tial therapeutic approaches for the reinvigoration of liver-resident
NK cells to limit CRLM growth.
Materials and Methods
Patient recruitment
Patients attending the National Liver Unit at St. Vincent's
University Hospital for hepatic metastasectomy secondary to
tumors of colorectal origin were eligible for inclusion in this
study. Eighteen patients were recruited preoperatively (Table 1).
Donor liver biopsies and liver perfusate (LP) samples were col-
lected during orthotopic liver transplantation (n ¼ 17; Table 1).
All patients provided written informed consent. This study was
carriedout in accordancewith theDeclarationofHelsinki andwas
reviewed and approved by the ethics committee of St. Vincent's
University Hospital.
Isolation of hepatic mononuclear cells from liver perfusate,
liver biopsy, and peripheral blood
Hepaticmononuclear cells (HMNCs)were isolated fromdonor
LP, as previously described (14, 30). Briefly, exsanguinated donor
livers were flushed and immersed in University of Wisconsin
solution for transport (transport medium). In theater, the donor
liver was flushed with saline to remove remaining transport
medium (flush). The transport medium and flush are combined
to make up the liver perfusate. HMNCs were then isolated by
density centrifugation after filtration of perfusate. HMNCs were
isolated from biopsies from tumor, tumor adjacent, and distal
tissue from hepatic resection for CRLM, by mechanical
and enzymatic digestion (collagenase type V, Sigma-Aldrich), as
previously described (31).
Preparation of liver-conditioned media
Donor liver biopsies and CRLM tumors were used to generate
tissue-conditioned media (CM) as previously described (24, 32).
Tissue was cut into sections approximately 5 mm3 and incubated
in 500 mL of RPMI-1640, with 10% fetal calf serum and 1%
penicillin/streptomycin (Gibco) for 72 hours at 37C. The super-
natant was centrifuged to remove cell debris and stored at80C
until use.
Phenotypic analysis of NK cells
HMNCs (1  105) were stained in FACS buffer for 30
minutes in the dark with fluorescently labeled monoclonal
antibodies to determine the phenotypic differences between
hepatic NK cells. A full list of antibodies used can be found in
Supplementary Table S1. Dead cell exclusion was performed
using fixable viability stain 780 (BD Biosciences). Mitochon-
drial mass was assessed using MitoTracker Deep Red (Thermo
Fisher); mitochondrial ROS production was measured using
MitoSox (Thermo Fisher). Flow cytometry analysis was per-
formed using an LSRFortessa, using fluorescence-minus-one
controls (FMO; BD Biosciences), and data were analyzed using
FlowJo (Version 7.6.5, Tree Star).
Isolation of NK-cell subset from liver perfusate
NK cells were isolated from fresh LP by FACS. Briefly, donor LP
was stained with monoclonal antibodies. NK cells were sorted
into two populations CD56bright CD16þ/ andCD56dim CD16þþ
using a FACSAria cell sorter (BD Biosciences).
Quantitative PCR
Total RNA was extracted from FACS-sorted NK cells from
LP and tissue from tumor and healthy tissue, using TRIzol
reagent (Thermo Fisher). Reverse transcription was performed
using the SuperScript VILO Master Mix (Thermo Fisher). Quan-
titative PCR was performed using primers for SLC16A1,
SLC16A3, and SLC2A1 (see Supplementary Table S1 for primer
sequences) using the PowerUp SYBR Green Master Mix (Thermo
Fisher) on a StepOnePlus Real-Time PCR System (Thermo Fish-
er). RPS15 and B2M were used as reference genes to generate
normalized relative expression values for target genes.
Cell line maintenance
The K562 and SW620 cell lines were purchased from ATCC
between 2008 and 2010. Experiments were performed on cells
less than 15 passages from purchase. Cells were routinely tested
for contamination using the LookOut Mycoplasma PCR Detec-
tion Kit (Sigma-Aldrich). Cell identity of 168 SW620 was per-
formed by IdentiCell (Denmark). Cell identity of K562 cells has
not been performed.
Cytoxicity assay
Target cells (K562or SW620)were labeledwithCellTrace Violet
(CTV). FACS-sorted liver NK cells were incubated with target cells
at a ratio of 2:1 for 4 hours. Anti-CD107a was added to assess
degranulation. Cytotoxicity was assessed by propidium iodide
staining (PI). CTVþ cells were gated, and PIþ cells were measured
as a percentage of target cells.
Table 1. Patient and organ donor demographics
CRLM patients N ¼ 18
Sex
Male (%) 12 (66)
Female (%) 6 (33)
Age
Median (range) 65 (50–79)
Number of liver metastases
Median (range) 2 (1–5)
Tumor size (mm)
Median (range) 22.5 (7–100)
Timing of CRLM
Synchronous 10
Metasynchronous 8
Neoadjuvant chemotherapy (%) 12 (66)
Disease recurrence, n¼ (%)
Yes 4 (22)
No 14 (78)
Organ donor N ¼ 17
Sex
Male 9
Female 8
Age
Median (range) 49 (28–67)
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Chemotaxis assay
Chemotaxis of liver NK cells was assessed using trans-
well inserts. Briefly, the lower chamber of the well was
filled with serum-free RPMI-1640 media supplemented
with 10% v/v CM. Liver NK cells (1  105) were applied
to the upper chamber. Plates were incubated for 2 hours at
37C. Cell numbers were assessed by flow cytometry using
123Count eBeads (eBiosciences) to enumerate absolute
cell counts.
Apoptosis assay
Apoptosis was assessed by annexin V/7-AAD staining. After
treatment, NK cells were placed in annexin staining buffer
and incubated for 20 minutes at RT with 2 mL annexin V. After
washing, 1 mL 7-AAD was added to each tube before
acquisition on flow cytometer. Apoptotic cells were defined
as annexin Vþ 7AADþ. Caspase 8 activity was blocked in
experiments using Z-IETD-FMK (BD Biosciences). Cells were
treated with Z-IETD-FMK (50 mmol/L) for 2 hours before the
addition of TCM for 24 hours. a-Cyano-4-hydroxycinnamic
acid (aCHC, Sigma-Aldrich) was used to block lactate trans-
port. aCHC (500 mmol/L) was administered for 2 hours
before the addition of TCM for 24 hours. MitoTempo
(Sigma-Aldrich), a mitochondrial ROS scavenger, was used
in further experiments. Cells were treated with MitoTempo
(50 mmol/L) for 2 hours before the addition of TCM for
either 2 or 24 hours.
Measurement of metabolites
Lactate concentrations were analyzed using a colorimetric
enzymatic assay (Sigma-Aldrich). The lactate determination kit
comes with premade lactate assay buffer, lactate probe, enzyme
mix, and standards. Samples were prepared and analyzed as per
the manufacturer's protocol. Briefly, CM samples were diluted
1:50 in lactate assay buffer. Sample (50 mL) was incubated with
50 mL reaction mixture for 30 minutes at RT. Absorbance was
measured at 570 nm. Similarly, glucose concentrations were
measured using an enzymatic assay as per the manufacturer's
instructions (Abcam). Conditioned media were diluted 1:50 in
glucose assay buffer and incubated with an equal volume of
reactionbuffer, at 37C for 30minutes. Absorbancewasmeasured
at 570 nm.
Intracellular pH measurement
Intracellular pH was measured using the pH sensitive dye
pHrodo (Thermo Fisher). This compound is retained within the
cytosol and becomes increasingly fluorescent as pH decreases.
Fluorescence was measured using flow cytometry. Controls
were established by treating NK cells with buffers of pH 7.5,
6.5, and 5.5.
Intracellular ATP measurement
Intracellular ATP was measured by luciferase assay
(Invitrogen). After treatment, NK cells were lysed using DTT
buffer. A luciferase construct, requiring ATP for activity, was used
to determine intracellular ATP concentrations. Luminescence was
measured using Fluoroskan Ascent FL (Labsystems).
ELISA
IL15 concentrations in CM were measured by ELISA according
to the manufacturer's instructions (PeproTech).
Statistical analysis
Statistical analysis was carried out using Prism GraphPad
Version 5.0. For comparison of two unmatched groups, Mann–
Whitney U test was used. Comparison of more than two
unmatched groups was performed using Kruskal–Wallis test, with
Dunn multiple comparison test. For paired comparisons, Fried-
man test with Dunnmultiple comparison tests was used formore
than two groups, and Wilcoxon signed rank test was used for
comparison of two matched groups. Within an experiment,
,  and  represent P< 0.05,P < 0.01, andP< 0.001, respectively.
Results
Liver-resident NK cells are depleted from colorectal liver
metastasis tumors
We have investigated the presence of liver-resident CD56bright
NK cells in CRLM tumors and surrounding tissue. NK cells are
significantly reduced in CRLM tumors (tumor 4.5%  0.8%,
adjacent 13.6%  1.9%, distal 15.6%  2.2%, P < 0.0001;
Fig. 1A–C). Patients with recurrent hepatic disease had signifi-
cantly lower intratumoral NK-cell numbers (recurrence: 41.2 
24.1/mg, no recurrence: 460.7 193.0/mg, P¼ 0.047; Fig. 1D). T
cells appear unaffected in CRLM, with no significant difference in
the population number throughout the tumor-bearing organ
(Fig. 1E and F). No correlation between T-cell infiltration of the
tumor and disease recurrence was observed (Fig. 1G). The largest
reduction in NK cells was seen from the liver-resident CD56bright
population (tumor 38.1% 3.4%, adjacent 50.8% 3.2%, distal
56.0%  3.2%, P ¼ 0.0009; Fig. 1H–J). This depletion of liver-
resident CD56bright NK cells was significantly worse in patients
who went on to develop recurrent CRLM (recurrence: 10.4 1.3/
mg, no recurrence: 204.7  124.2/mg, P ¼ 0.0238; Fig. 1K).
Liver-resident NK cells display an activated phenotype com-
pared with conventional CD56dim cells isolated from liver per-
fusate. They display increased expression of activation markers,
including NKG2D, NKp46, and NKp44 (Supplementary
Fig. S1A–F). They express cytotoxic molecules such as perforin,
granzyme B, granzyme A, and granzyme K (Supplementary
Fig. S1G–K).Despite lower expression of granzymeB andperforin
compared with CD56dim NK cells from liver perfusate, liver-
resident CD56bright NK cells degranulate significantly more in
response to tumor cells and are capable of direct cytotoxicity
against the metastatic colorectal cell line SW620, equal to
CD56dim NK cells (Supplementary Fig. S1L–O).
Tumor-infiltrating CD56bright NK cells have liver-resident
phenotype
The remaining CD56bright NK cells maintained a tissue-
resident phenotype (Eomeshi Tbetlo; Fig. 2A and B) throughout
the tumor-bearing tissue. In addition, they maintained expres-
sion of other markers of tissue residency, including CXCR6,
CD69, CD49a, and TRAIL (Fig. 2C–G). This indicated that
CD56bright NK cells were not infiltrating peripheral blood cells
and that liver-resident NK cells throughout the liver may be
activated in CRLM. A decrease in the absolute count of
CD56dim NK cells was also observed in the tumor; however,
the scale of this change was smaller than liver-resident NK cells
(Supplementary Fig. S2A–C). The remaining CD56dim cells
were Eomeslo Tbethi and failed to highly express markers of
tissue residency, CXCR6, CD69, and CD49a. However, they
did express TRAIL, which may indicate an activated phenotype
Liver NK Cells Undergo Apoptosis in Tumor Microenvironment
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(Supplementary Fig. S2D–H). Tumor-infiltrating liver-resident
NK cells displayed increased expression of NKp44 (a marker of
NK-cell activation) but no associated increase in activating
receptors such as NKG2D, NKp46, or NKG2C (Fig. 3A–E). We
next analyzed the expression of cytotoxic molecules in
liver-resident NK cells from tumor-bearing liver. Similar
expression of perforin, granzyme A, granzyme B, or granzyme
K was observed in each site, indicating that cytotoxic potential
was maintained in tumor-infiltrating CD56bright NK cells
(Fig. 3F–J).
Figure 1.
Depletion of liver-resident NK cells
is evident in CRLM and correlates
with CRLM recurrence.
Mononuclear cells isolated from
tumor, adjacent, and distal tissue
samples were stained with
monoclonal antibodies. Gating
strategy: NK cells were identified
from the CD45þ lymphocyte gate
as CD56þCD3. We then gated
CD56bright CD16–/þ and CD56dim
CD16þ subsets. T cells were
identified as CD3þ CD56 lymphoid
cells. Absolute counts were
established using 123Count eBeads.
A, Representative dot plots of
lymphoid populations in samples
from tumor, adjacent, and distal
tissue. B, The percentage of NK
cells in tumor, adjacent, and distal
tissue (n¼ 18). C, Absolute counts
of NK cells per milligram of tissue
from tumor, adjacent, and distal
samples (n¼ 9). D,Absolute counts
of NK cells per milligram of tissue in
patients with hepatic recurrence
(n¼ 3) and no recurrence (n¼ 6).
E, The percentage of T cells in
tumor, adjacent, and distal tissue
(n¼ 18). F,Absolute counts of T
cells per milligram of tissue from
tumor, adjacent, and distal samples
(n¼ 9).G, Absolute counts of T
cells per milligram of tissue in
patients with hepatic recurrence
(n¼ 3) and no recurrence (n¼ 6).
H, Representative dot plots of
NK-cell subsets in tumor, adjacent,
and distal tissue. I, CD56bright
CD16–/þNK-cell frequencies in
tumor, adjacent, and distal tissue
(n¼ 18). J,Absolute counts of
CD56bright NK cells per milligram of
tissue from tumor, adjacent, and
distal samples (n¼ 9). K, Absolute
counts of CD56bright NK cells per
milligram of tissue in patients with
hepatic recurrence (n¼ 3) and no
recurrence (n¼ 6). Data presented
as mean SEM. Data were
analyzed using the Friedman
test, with Dunn multiple
comparison test (B, C, E, F, I, J)
or Mann–Whitney U test (D, G, K)
( , P < 0.05;  , P < 0.01;
, P < 0.001).
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Liver-resident NK cells undergo apoptosis in the tumor
microenvironment
To address the depletion of NK cells from CRLM tumors, we
used a CM culture system to identify the mechanism by which
CD56bright NK cells are lost from tumor tissue. Tumor and donor
liver tissuewere cultured for 72hours, and supernatantswere used
to treat NK-cell subsets isolated from donor liver perfusate.
Treatment with CRLM-CM had no effect on the migration ability
of the liver-resident NK cells in vitro (Supplementary Fig. S3A–
S3C). CD56dim NK cells had a reduced capacity tomigrate toward
TCM compared with healthy LCM, possibly accounting for their
decreased numbers in CRLM tumors (Supplementary Fig. S3D).
In the absence of a defect in migration, we hypothesized
that the tumor microenvironment was inducing apoptosis of
liver-resident NK cells. NK-cell subsets from donor liver
perfusate were treated with liver (LCM) and CRLM (TCM)
CM for 24 hours. There was a significant increase in the
proportion of late apoptotic (Annexin Vþ/7-AADþ) liver-
resident NK cells treated with TCM compared with LCM but
no change in early apoptotic cells (LCM: 21.1%  2.8%,
TCM: 39.2%  8.1%, P ¼ 0.034; Fig. 4A–C), with no similar
increase observed in CD56dim NK cells (P ¼ 0.92; Fig. 4D
and E). The proportion of late apoptotic cells was signifi-
cantly higher in CD56bright NK cells treated with TCM,
compared with CD56dim cells (Fig. 4F). This apoptosis
was not reversible when extrinsic cell signals (i.e., TRAIL,
Fas signaling) were blocked through the Caspase 8 inhibitor
Z-IETD-FMK (P ¼ 0.88; Fig. 4G).
The tumor microenvironment can be inhospitable to
immune cells due to the reduced availability of growth factors,
Figure 2.
Tumor-infiltrating CD56bright NK cells maintain a liver-resident phenotype. A, Representative dot plots of Eomes and Tbet expression in CD56bright NK cells in
samples from tumor, adjacent, and distal tissue. B, The percentage of Eomeshi Tbetlo CD56bright NK cells in tumor, adjacent, and distal tissue. C, Representative
histograms of CXCR6, TRAIL, CD69, and CD49a in CD56bright NK cells in samples from tumor (solid line), adjacent (dotted line), and distal tissue (dashed line;
black filled bar, FMO). D, The percentage of CXCR6þCD56bright NK cells in tumor, adjacent, and distal tissue. E, The percentage of CD69þCD56bright NK cells in
tumor, adjacent, and distal tissue. F, The percentage of CD49aþCD56bright NK cells in tumor, adjacent, and distal tissue. G, The percentage of TRAILþCD56bright
NK cells in tumor, adjacent, and distal tissue. Data presented as mean SEM. Data were analyzed using the Friedman test, with Dunn multiple comparison test.
(B, n¼ 6; D–G, n¼ 5).
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Figure 3.
Remaining tumor-infiltrating CD56bright NK cells are activated and express the proteins required for cytotoxic responses. A, Representative histograms of
NKG2D, NKp46, NKp44, and NKG2C in CD56bright NK cells in samples from tumor (solid line), adjacent (dotted line), and distal tissue (dashed line; black filled bar,
FMO). B, The percentage of NKG2DþCD56bright NK cells in tumor, adjacent, and distal tissue. C, The percentage of NKp46þCD56bright NK cells in tumor, adjacent,
and distal tissue. D, The percentage of NKp44þCD56bright NK cells in tumor, adjacent, and distal tissue. E, The percentage of NKG2CþCD56bright NK cells in tumor,
adjacent, and distal tissue. F, Representative histograms of granzyme B, perforin, granzyme A, and granzyme K in CD56bright NK cells in samples from tumor
(solid line), adjacent (dotted line), and distal tissue (dashed line; black filled bar, FMO). G, The expression of granzyme B in CD56bright NK cells from tumor,
adjacent, and distal tissue. H, The expression of perforin in CD56bright NK cells from tumor, adjacent, and distal tissue. I, The expression of granzyme A in
CD56bright NK cells from tumor, adjacent, and distal tissue. J, The expression of granzyme K in CD56bright NK cells from tumor, adjacent, and distal tissue. Data
presented as mean SEM. Data analyzed using the Friedman test, with Dunn multiple comparison test (n¼ 5;  , P < 0.05).
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essential amino acids, and metabolites. We therefore investi-
gated whether liver-resident NK cells showed signs of mito-
chondrial stress in the CRLM tumor microenvironment. There
is a decrease in the mitochondrial mass of CD56bright NK cells
in CRLM tumors compared with surrounding tissue, which is
not seen in tumor-infiltrating CD56dim NK cells (Fig. 4H–J).
This is accompanied by the production of mitochondrial ROS,
which is significantly increased in tumor-infiltrating CD56bright
NK cells compared with surrounding tissue (Fig. 4K–L). This is
not the case with CD56dim NK cells, which do not produce
mitochondrial ROS (Fig. 4M). Mitochondrial mass is signifi-
cantly lower in liver-resident NK cells compared with CD56dim
NK cells in liver perfusate (Supplementary Fig. S4A and B),
suggesting an intrinsic difference in metabolic activity may
underpin the sensitivity of liver-resident CD56bright NK cells
to apoptosis.
We next attempted to identify the factor responsible for
inducing mitochondrial stress in tumor-infiltrating NK cells.
NK cells are dependent on IL15 for survival, and withdrawal of
this growth factor can cause mitochondrial dysfunction. How-
ever, in supernatant from CRLM, IL15 was detected at similar
concentrations to donor tissue (TCM: 335.6  74 pg/mL, LCM:
300  15.4 pg/mL, P ¼ 0.84; Fig. 4N). Availability of glucose
in the tumor microenvironment can also be a rate-limiting
step in immune activation and survival; however, in this
in vitro system glucose did not differ between the LCM and
Figure 4.
Liver-resident NK cells undergo apoptosis, via intrinsic cell death signaling, associated with elevated lactate in the CRLM tumor microenvironment. Healthy liver-
resident NK cells and conventional NK cells were isolated from donor liver perfusate. Cells were cultured with 50% v/v CM from CRLM tumors (TCM) or donor
liver biopsies (LCM) for 24 hours. Apoptosis was assessed by annexin V and 7-AAD staining. A, Representative dot plots of annexin V/7AAD staining in CD56bright
and CD56dim NK cells treated with LCM or CRLM. B, Percentage of early apoptotic CD56bright NK cells after treatment with LCM or TCM. C, Percentage of late
apoptotic CD56bright NK cells after treatment with LCM or TCM. D, Percentage of early apoptotic CD56dim NK cells after treatment with LCM or TCM.
E, Percentage of late apoptotic CD56dim NK cells after treatment with LCM or TCM. F, Percentage of late apoptotic NK-cell subsets after treatment with TCM.
CD56bright NK cells were pretreated with caspase 8 inhibitor Z-IETD-FMK for 2 hours before 24 hours of culture. G, Percentage of late apoptotic CD56bright NK
cells after treatment with TCMwith/without Z-IETD-FMK. NK cells from tumor-bearing tissue were assessed for evidence of mitochondrial stress.
H, Representative histograms of MitoTracker in CD56bright NK cells in samples from tumor (solid line), adjacent (dotted line), and distal tissue (dashed line; black
filled bar, FMO). I,MitoTracker staining inCD56bright NK cells in tumor, adjacent, and distal tissue. J,MitoTracker staining inCD56dim NK cells in tumor, adjacent,
and distal tissue. K, Representative histograms of MitoSox in CD56bright NK cells in samples from tumor (solid line), adjacent (dotted line), and distal tissue
(dashed line; black filled bar, FMO). L, The percentage of MitoSox positiveCD56bright NK cells in tumor, adjacent, and distal tissue.M, The percentage of MitoSox
positiveCD56dim NK cells in tumor, adjacent, and distal tissue. CM from donor livers (LCM) and colorectal liver metastasis (TCM) were generated and analyzed for
cytokines and metabolites.N, IL15 concentration in LCM and TCM.O, Glucose concentration in LCM and TCM. P, Lactate concentration in LCM and TCM.Q, pH
measurement of LCM and TCM. Data presented as mean SEM. Data were analyzed usingWilcoxon matched pairs test (B–G), Mann–Whitney U test (N–P) or
Friedman test, with Dunn multiple comparison test (I–M). A–M, n¼ 5;N–P, n¼ 10;  , P < 0.05;  , P < 0.01.
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TCM but may play a greater role in vivo (TCM: 17.1  3.6
mmol/L, LCM: 17.2  1.5 mmol/L, P ¼ 0.49; Fig. 4O). Fur-
thermore, expression of glucose transporter (GLUT1),
amino acid transporter (CD98), and transferrin receptor
(CD71) did not differ between donor NK-cell subsets and
was unchanged in tumor-infiltrating CD56bright NK cells,
which indicates nutrient availability may not be drastically
altered (Supplementary Fig. S5A–H). Despite comparable
concentrations of glucose, CRLM tumors appeared more
glycolytically active compared with nontumor tissue,
producing significantly higher concentrations of lactate (TCM:
11.5  2.8 mmol/L (range, 1.59–24.9 mmol/L), LCM: 1.7 
0.3 mmol/L, P ¼ 0.002; Fig. 4P) and increased expression
of GLUT1 mRNA in tumor samples compared with adjacent
tissue, as well as increased expression of the lactate transporter
SLC16A3 (Supplementary Fig. S6A–S6C). This increased
production of lactate led to a significant decrease in the
pH of CM (TCM: pH 6.6  0.16, LCM: pH 7.4  0.08,
P ¼ 0.0043; Fig. 4Q).
Tumor-derived lactic acid induces ROS-mediated apoptosis of
CD56bright NK cells
We used two forms of lactate to investigate its effect on donor
liver–resident NK cells, sodium lactate (basic form), and lactic
acid (acidic form) at 10 and 20 mmol/L. No significant change
was observed in the proportion of early apoptotic NK cells under
any condition tested (Supplementary Fig. S7A–S7G). Sodium
lactate did not induce an increase in late apoptotic cells in either
CD56bright or CD56dim NK cells (Fig. 5A and B). Lactic acid
induced a significant increase in late apoptotic CD56bright NK
cells (media: 13.5%  2.8%, 10 mmol/L lactic acid: 20.7% 
4.6%, 20 mmol/L lactic acid: 43.4%  9.1%, P ¼ 0.01; Fig. 5C)
but not in CD56dim NK cells (Fig. 5D). In order to determine if
this process was pH mediated, medium was altered to pH 7.4
Figure 5.
Lactic acid induces apoptosis of liver-resident NK cells by reducing intracellular pH resulting in the accumulation of mitochondrial ROS. Healthy liver-resident
NK cells and conventional NK cells were isolated from donor liver perfusate. Cells were cultured for 24 hours in the presence of 10 or 20mmol/L sodium lactate
or lactic acid or media with pH 7.4 or 6.4. Apoptosis was assessed by annexin V and 7-AAD staining. A, Percentage of late apoptotic CD56bright NK cells after
treatment with sodium lactate. B, Percentage of late apoptotic CD56dim NK cells after treatment with sodium lactate. C, Percentage of late apoptotic CD56bright
NK cells after treatment with lactic acid. D, Percentage of late apoptotic CD56dim NK cells after treatment with lactic acid. E, Percentage of late apoptotic
CD56bright NK cells after culture in media pH 7.4 or 6.4. F, Percentage of late apoptotic CD56dim NK cells after culture in media pH 7.4 or 6.4. CD56bright NK cells
were cultured for 2 hours in the presence of 10 or 20mmol/L lactic acid.G, Representative histogram of pHrodo staining in CD56bright cultured in media
(dashed line), 10 mmol/L lactic acid (dotted line), or 20mmol/L lactic acid (solid line). H, Intracellular pH of CD56bright cells cultured in media, 10 mmol/L lactic
acid, or 20 mmol/L lactic acid. I, Percentage of MitoSox-positive CD56bright cells cultured in media, 10 mmol/L lactic acid, or 20mmol/L lactic acid.
J, Concentration of ATP in CD56bright NK cells cultured in media, 10 mmol/L lactic acid, or 20mmol/L lactic acid. CD56bright NK cells were cultured for 2 hours in
the presence of LCM or TCM. K, Intracellular pH of CD56bright cells cultured in LCM or TCM. L, Percentage of MitoSox-positive CD56bright cells cultured in LCM
or TCM. Data presented as mean SEM. Data were analyzed using Friedman test, with Dunn multiple comparison test (A–J), or Mann–Whitney U test (K–L).
n¼ 5; , P < 0.05;  , P < 0.01.
Harmon et al.
Cancer Immunol Res; 7(2) February 2019 Cancer Immunology Research342
on March 23, 2020. © 2019 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Published OnlineFirst December 18, 2018; DOI: 10.1158/2326-6066.CIR-18-0481 
and 6.4 to mimic the pH of normal tissue and tumor tissue
with 20 mmol/L lactic acid. Liver-resident CD56bright NK cells
undergo significantly higher frequency of apoptosis in pH 6.4
(media: 11.5%  2.7%, pH 7.4: 23.9%  6.5%, pH 6.4:
32.9%  5.9%, P ¼ 0.041; Fig. 5E). Apoptosis did increase in
CD56dim NK cells; however, this was not statistically significant
(Fig. 5F). Although there appears to be a trend toward increased
apoptosis in CD56dim NK cells treated with lactic acid and low
pH media, this was not significant and highlights the increased
susceptibility of liver-resident CD56bright NK cells to these
environments.
In order to determine the mechanism by which CD56bright NK
cells undergo apoptosis, donor liver–resident NK cells were
treated with lactic acid for 2 hours at 10 and 20 mmol/L. After
2 hours, the intracellular pH of NK cells decreases significantly
(media: pH 7.4  0.15, 10 mmol/L lactic acid: pH 6.9  0.2,
20 mmol/L lactic acid: pH 6.5 0.4, P¼ 0.0046; Fig. 5G and H).
This was accompanied by an increase in mitochondrial ROS
production, similar to that seen inNK fromCRLM tumor samples
(media: 10.4%  1.9%, 10 mmol/L lactic acid: 13.3%  2.6%,
20 mmol/L lactic acid: 20.0%  0.9%, P ¼ 0.021; Fig. 5I). In
addition, intracellular ATP dropped significantly in lactic acid–
treated cells (media: 1070  334 pmol/105 cells, 10 mmol/L
lactic acid: 688  230 pmol/105 cells, 20 mmol/L lactic acid:
589 178 pmol/105 cells, P¼ 0.008; Fig. 5J). Furthermore, when
liver-resident NK cells were treated with TCM for 2 hours, a
decrease in intracellular pH was observed (TCM: pH 6.1 
0.15, LCM: pH 7.38  0.16, P ¼ 0.018; Fig. 5K), accompanied
by the production of mitochondrial ROS (TCM: 16.5%  3.5%,
LCM: 5.3%  0.86%, P ¼ 0.037; Fig. 5L). Together, these results
indicate that lactic acid in the tumor microenvironment causes
pH-dependent mitochondrial stress and metabolic dysfunction,
which promotes apoptosis.
Liver-resident NK-cell apoptosis is ROS mediated but does not
require lactate transport
We next attempted to block lactate transport using a-cyano-4-
hydroxycinnamic acid (aCHC). However, pretreatment with
aCHC did not reduce mitochondrial ROS production after expo-
sure to lactic acid (Fig. 6A and B). Furthermore, NK-cell subsets do
not differ in their expression of lactate transporters SLC16A1 or
SLC16A3 (Fig. 6C and D). These results indicate that the effects of
lactic acid were independent of transport into the cell and are
more likely related to changes in the pHof themicroenvironment.
In order to determine whether NK-cell apoptosis was ROS
mediated, we utilized MitoTempo, a mitochondria-specific
ROS scavenger. Treatment with MitoTempo significantly
reduced mitochondrial ROS (lactic acid: 36.1%  9.3%, lactic
acidþMitoTempo: 18.0% 8.5%, P¼ 0.002; Fig. 6E and F) and
rescued liver-resident NK cells from apoptosis after 24-hour
treatment with lactic acid, decreasing the proportion of
late apoptotic cells (lactic acid: 30.7%  2.5%, lactic acid þ
MitoTempo: 18.1%  2.0%, P ¼ 0.0013; Fig. 6G–I).
Discussion
In this study, we have characterized the NK-cell repertoire of
tumor-bearing liver in patients with CRLM and demonstrated a
significant depletion of liver-resident NK cells from CRLM
tumors. We have evidence that NK-cell depletion correlates with
Figure 6.
Lactic acid induced apoptosis of liver-resident NK cells can be prevented by treatment with ROS scavenger MitoTempo. Healthy liver-resident NK cells were
isolated from donor liver perfusate and pretreated with a lactate transport inhibitor (aCHC, 500 mmol/L) or ROS scavenger (MitoTempo, 50 mmol/L) for 2 hours.
Lactic acid was then added to cultures at 20mmol/L for 2 or 24 hours. A, Representative histogram of MitoSox staining in CD56bright cultured in lactic acid
20mmol/L (solid line) or aCHC and 20mmol/L lactic acid (dotted line). B, Percentage of MitoSoxþ CD56bright cells cultured in 20mmol/L lactic acid or aCHC and
20mmol/L lactic acid (n¼ 3). Real-time PCRwas performed on sorted NK subsets from liver perfusate. Gene expression was normalized to internal control
RPS15. C, Expression ofSLC16A1 (MCT1) in CD56bright and CD56dim NK cells. D, Expression ofSLC16A3 (MCT4) in CD56bright and CD56dim NK cells (n¼ 5).
E, Representative histogram of MitoSox staining in CD56bright lactic acid 20mmol/L (solid line) or MitoTempo and 20mmol/L lactic acid (dotted line).
F, Percentage of MitoSox-positive CD56bright cells cultured in lactic acid 20 mmol/L or MitoTempo and 20mmol/L lactic acid (n¼ 5). G, Representative dot plot
of annexin V/7-AAD staining in CD56bright NK cells treated with lactic acid 20mmol/L or MitoTempo and 20mmol/L lactic acid. H, Percentage of early
apoptotic CD56bright cells cultured in lactic acid 20mmol/L or MitoTempo and 20 mmol/L lactic acid. I, Percentage of late apoptotic CD56bright cells cultured in
lactic acid 20mmol/L or MitoTempo and 20mmol/L lactic acid (n¼ 5). Data presented as mean SEM. Data were analyzed using theWilcoxon matched
pairs test.  , P < 0.01.
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CRLM recurrence. This depletion is induced by an accumulation
of lactate in the tumor microenvironment, causing a reduction in
intracellular pH in hepatic NK cells, leading to mitochondrial
dysfunction and apoptosis.
NK cells are essential components of the hepatic antitumor
immune repertoire. Liver NK cells have been shown to be cyto-
toxic against tumor cells and should provide the liver with ample
antitumor immunity (33–35). The liver-resident NK-cell subpop-
ulation displays increased expression of cytotoxicity receptors,
expresses cytotoxic molecules, and is capable of similar direct
cytotoxicity against SW620 cells, comparedwith conventional NK
cells. Furthermore, TRAIL expression was significantly increased
throughout the tumor-bearing liver, indicating that NK-cell
immunosurveillance is heightened in CRLM.
Previous reports have been contradictory, with one claiming
that the presence of NK cells in CRLM is correlated with a reduced
life expectancy (36) and another with improved disease outcome
(20). However, specific NK-cell subsets were not investigated in
either of these studies, perhaps accounting for the opposing
conclusions. Here, we have identified a significant reduction in
liver-resident NK cells from CRLM tumors, despite effective
migration toward CRLM-CM. This depletion correlated with
hepatic recurrence postresection. This finding parallels results
from primary colorectal cancer tumors, which are relatively
devoid of NK cells, with surrounding tissue containing normal
frequencies of NK-cell populations (21).
We hypothesized that NK cells undergo apoptosis after migra-
tion into the tumor microenvironment. Ex vivo tumor-infiltrating
CD56bright NK cells displayed increased mitochondrial ROS pro-
duction and decreased mitochondrial mass compared with cells
from surrounding tissue and infiltrating CD56dimNK cells. CRLM
tumors appear highly glycolytic, with higher GLUT1 expression,
lactate transporters, and extracellular lactate. Lactate is produced
by tumor cells during Warburg metabolism and is then exported
via monocarboxylate transporters (MCT1/4) along with protons,
lowering the extracellular pH (26). In vitro, lactic acid induced
significant apoptosis of liver-resident NK cells. The acidic envi-
ronment provoked a change in intracellular pH of liver-resident
NK cells, production of mitochondrial ROS, and reduced ATP
generation, inducing intrinsic ROS-mediated apoptosis. Lactate is
a potent immune modulator in the tumor microenvironment,
known to polarize macrophages and neutrophils, suppress DC
activity, and dysregulate and kill T and NK cells (29, 37–40), and
our results implicate lactate as the intrinsic cell death signal for
liver-resident NK cells. Mechanistically, our results are similar to
that described in murine NK cells in a metastatic B16 melanoma
model by Brand and colleagues (29), and our results extend on
this work to illustrate how a ROS scavenger (MitoTempo) is able
to mitigate the effect of pH-induced damage and prevent apo-
ptosis in human tissue-resident NK cells. This result highlights the
potential of targeting lactate and the microenvironment pH in
order to treat metastatic malignancies in humans.
Reasons for increased liver-resident NK-cell susceptibility to
pH induced cellular stress compared with CD56dim NK cells are
unknown. Lymphocytes have been shown to be capable of
maintaining intracellular pH in acidic conditions to a certain
point (pH 6.8; ref. 41). HCO provides most of the buffering
capacity in the cell and is produced from CO2 generated from
mitochondrial respiration (42). Cells with greater mitochon-
drial mass and an active TCA cycle produce more CO2 and have
greater buffering capacity. We have shown that liver-resident NK
cells have significantly lower mitochondrial mass, and increased
mitochondrial ROS production, compared with CD56dim NK
cells, reducing their capacity to generate CO2, possibly making
them more susceptible to extracellular pH changes.
The recurrence of CRLM after successful resection occurs in up
to 70% of patients. Evidently, immune surveillance mechanisms
in the liver remain compromised after removal of the tumor.
We found that disease recurrence correlates with reduced NK-cell
numbers in CRLM tumors, more so than T cells in the intestine,
which predict colorectal cancer outcome (17, 18). Treatment
targeting lactate productionmaybenefit these patients, improving
immune surveillance in the liver and limiting future tumor
growth. We believe this approach will substantially reduce the
recurrence rate after surgical resection.
Targeting metabolic pathways in oncology is not a new
therapeutic concept, and the use of antimetabolites such
as methotrexate, folic acid, or 5-fluorouracil is a common
treatment for many cancers, despite their toxicity (43). A
lactate-mediated mechanism, by which CRLM subverts local
antitumor immunity, provides new opportunities for
therapies that target specific metabolic pathways. Inhibition
of glycolysis in tumor cells is of growing interest to oncolo-
gists; however, identifying components in this pathway that
specifically inhibit tumor growth and spare immune cells is
challenging. In preclinical testing, drugs that target GAPDH
(Koningic acid) and LDH (FX11) are effective in limiting
tumor growth (43–45). The use of systemic bicarbonate buff-
ering, which neutralizes tumor acidity, has been reported
to reduce tumor invasiveness and improve NK-cell responses
(46, 47); however, patient adherence to treatment can prove
difficult. Alternatively, lactate transport can be targeted spe-
cifically (AZD3965, NCT01791595) to prevent release of lac-
tate from tumor cells, increasing it to toxic concentrations
within tumor cells, reducing their growth, and inducing their
apoptosis (48–50).
Our results highlight the immunosurveillance role of liver-
resident NK cells, which are depleted in patients with recurrent
CRLM. This depletion is driven by tumor-derived lactate, iden-
tifying a potential immunometabolic therapeutic target in
patients with CRLM. Therapies capable of reducing lactate
concentrations within the tumor microenvironment may
restore liver-resident NK-cell populations, benefiting patients
with both resectable CRLM and inoperable CRLM, by reducing
tumor growth and restoring local tumor immunity. We believe
this approach could substantially reduce the recurrence rate
after surgical resection.
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